⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1650778 | 1.00 | — | — | |
| SCHEMBL6998150 | 1.00 | — | — | |
| SCHEMBL17224577 | 0.98 | CYP2D6 (0.39) | — | |
| SCHEMBL6186602 | 0.82 | — | — | |
| SCHEMBL28763835 | 0.82 | — | — | |
| SCHEMBL890128 | 0.82 | — | — | |
| SCHEMBL890097 | 0.82 | — | — | |
| SCHEMBL1745137 | 0.80 | CYP2D6 (0.36) | — | |
| Lithium Ion SCHEMBL17224576 | 0.80 | — | — | |
| SCHEMBL1745139 | 0.80 | CYP2D6 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3985001-B1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING A CANCER | SERVIER LAB (FR) | 2026-04-29 | — | — | EP | disclosed |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | ARTIOS PHARMA LIMITED (GB) | 2025-07-15 | — | — | US | disclosed |
| CN-107556366-B | Compound having mutant isocitrate dehydrogenase inhibitory activity, process for producing the same, and use thereof | 上海海和药物研究开发股份有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-114667167-B | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-12-20 | — | — | CN | disclosed |
| WO-2024237696-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NONTUBERCULOUS MYCOBACTERIA INFECTION COMPRISING CD36 INHIBITOR | 한국생명공학연구원 | 2024-11-21 | — | — | WO | disclosed |
| US-20240059733-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC (US) | 2024-02-22 | — | — | US | disclosed |
| EP-4010080-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| EP-4010080-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| EP-1019400-B1 | BENZO(5,6)CYCLOHEPTAPYRIDINE COMPOUNDS USEFUL AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORP (US) | 2004-08-11 | — | — | EP | disclosed |
| US-6441189-B1 | WHICH REDUCES RACEMIZATION; (4R)-4-(HYDROXYMETHYL)-1,3-OXAZOLIDIN-2-ONE BY REDUCTION AND BASIFICATION OF THE CORRESPONDING 4-PROTECTED CARBOXY ESTER | ABBOTT LABORATORIES | 2002-08-27 | — | — | US | disclosed |
| US-20020052511-A1 | Process for the preparation of matrix metalloproteinase inhibitors | BAILEY ANNE E (US) | 2002-05-02 | — | — | US | disclosed |
| US-20020019539-A1 | Process for the preparation of matrix metalloproteinase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
| WO-2001074792-A2 | PROCESS FOR THE PREPARATION OF MATRIX METALLOPROTEINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-11 | — | — | WO | disclosed |
| EP-1019400-A1 | BENZO(5,6)CYCLOHEPTAPYRIDINE COMPOUNDS USEFUL AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2000-07-19 | — | — | EP | disclosed |
| US-5939416-A | INHIBIT RAS FUNCTION, USE FOR TREATING TUMOR CELLS EXPRESSING AN ACTIVATED RAS ONCOGENE IN MAMMALS | SCHERING CORPORATION (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1998057970-A1 | BENZO(5,6)CYCLOHEPTAPYRIDINE COMPOUNDS USEFUL AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
| US-5356918-A | Oxazolidinone compounds and method of using the same as a vasodilator | SANKYO COMPANY, LTD. (JP) | 1994-10-18 | — | — | US | disclosed |
| US-5298516-A | Treatment of cardiovascular disorders, angina | SANKYO COMPANY, LIMITED (JP) | 1994-03-29 | — | — | US | disclosed |